Ad-hoc | 8 March 2018 07:42
Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
|
Evotec AG / Key word(s): Miscellaneous
Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that Evotec and Sanofi have entered into exclusive negotiations to accelerate infectious disease research and development through a new open innovation platform led by Evotec. Sanofi will licence its infectious disease research and early-stage development portfolio and transfer its infectious disease research unit, which includes more than 100 employees to Evotec. Sanofi will pay Evotec an initial one-time cash upfront payment of EUR 60 m and provide further significant long-term funding to ensure support and progression of the portfolio. Sanofi will retain certain option rights on the development, manufacturing, and commercialisation of anti-infective products. This transaction is expected to close in the first half of 2018, subject to finalisation of definitive agreements and completion of the appropriate social process. Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, werner.lanthaler@evotec.com
08-March-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|
| Language: | English |
| Company: | Evotec AG |
| Manfred Eigen Campus / Essener Bogen 7 | |
| 22419 Hamburg | |
| Germany | |
| Phone: | +49 (0)40 560 81-0 |
| Fax: | +49 (0)40 560 81-222 |
| E-mail: | info@evotec.com |
| Internet: | www.evotec.com |
| ISIN: | DE0005664809 |
| WKN: | 566480 |
| Indices: | TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| End of Announcement | DGAP News Service |